期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

辛伐他汀治疗后糖化血红蛋白对血脂的影响 被引量：6

EFFECT OF BLOOD HBA1C ON LIPIDEMIA IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH SIMVASTATINE
下载PDF
导出
摘要 目的探讨2型糖尿病患者用辛伐他汀降脂治疗后血糖控制状况对血脂的影响。方法对93例住院的已行辛伐他汀降血脂治疗的2型糖尿病患者的糖化血红蛋白(HbA1c)、血脂进行分析,将病人分为HbA1c升高组和HbA1c正常组,观察HbA1c浓度对血脂的影响。结果辛伐他汀降血脂治疗后2型糖尿病患者HbA1c升高组的TRIG较高,HDLC和APOA较低,且均有显著性差异(p<0.05),而CHOL、LDLC和APOB在两组间无显著性差异。结论2型糖尿病患者经辛伐他汀降血脂治疗后,血糖水平对的血脂影响仍然存在,因此降脂治疗的同时应注意血糖对血脂的影响。 Objective To investigate lipidemia disorder and effect of glucose on lipidemia in patients with type 2 diabetes （T2DM） treated with Statin. Methods 93 patients with T2DM were enrolled and the levels of blood lipid （ TRIG, CHOL, HDLC, LDLC, APOA, APOB ）, HbAlc were measured. Results HbAlc was correlated with TRIG positively （p 〈 0.05 ） ; and correlated with HDLC and APOA negatively （p 〈0. 05 ）. And there were no significant difference of CHOL, LDLC and APOB between the two groups. Conclusion In patients with T2DM treated with Statin the influence of blood glucose on lipid is existing. The levels of glucose and lipid should be both controlled to prevent atheroselerosis.
作者 卓胜青 杨雪苹 陈勇驰 杨辉剑 连环 龚彩平
机构地区 广东省人民医院广东省老年医学研究所
出处 《现代医院》 2009年第1期27-28,共2页 Modern Hospitals
关键词 2型糖尿病 糖化血红蛋白 血脂 Diabetes mellitus, HbAlc, Blood - lipid
分类号 R587.1 [医药卫生—内分泌] R972.6 [医药卫生—药品]
  • 相关文献

参考文献4

二级参考文献29

  • 1潘时中,倪达人,严孙杰,王敏,赵淑好,刘东晖.糖尿病患者骨代谢的变化[J].福建医学院学报,1993,27(4):328-330. 被引量：4
  • 2刘丽森,齐今吾.糖尿病性骨质疏松与钙代谢调节因素的关系[J].中华内分泌代谢杂志,1993,9(3):183-184. 被引量：26
  • 3[1]Expert committee on the diagnosis and classification of diabetes mel litus:report of the expert committee on the diagnoris and classification of diabetes mellitus. Diabetes Care, 1997,20:1183.
  • 4[2]Davies M:New diagnostic criteria for diabetes. Are they doing what they should? Lancet, 1999,354 : 610.
  • 5[3]De Vegt F, Dekker JM,Jager A, et al. Relation of impaired fasting and post load glucose with incident type 2 diabetes in a Dutch population. The Hoorn. JAMA, 2001,285: 2109.
  • 6[4]Glucose tolerance and cardiovascular mortality :Comparison of fasting and 2h diagnostic criteria. Arch Intern Med, 2001,161: 397.
  • 7[5]Eschwege E,Charles MA,Simon D,et al. Reproducibility of the diagnosis of diabetes over a 30-month follow-up. The Paris prespective study, Diabetes Care, 2001,24:1941.
  • 8[6]Eschwege E,Chasles MA, Simon D,et al. From policement to policies :What is the future for 2h Glucose?Diabetes care, 2001,24:1945.
  • 9[7]Gerstein HC. Fasting verus postload glucose levels. Why the controvery? Diabeter care, 2001,24 : 1855.
  • 10[8]Coutinho M,Gerstein HC,Wang Y, et al. The relationship between glucose and incident cardiovascular events:a metaregression analysis of published data from 20 studies of 95,783 individvals followed for 12. 4 years. Diabetes care,1999,22:233.

共引文献116

同被引文献43

  • 1甄毅锋,梁素娥.老年2型糖尿病病人低密度脂蛋白达标分析[J].中西医结合心脑血管病杂志,2006,4(7):632-633. 被引量：2
  • 2张柳,刘锋,梁春雨,赵文国.辛伐他汀对卵巢切除大鼠股骨骨折愈合作用的影响[J].第四军医大学学报,2007,28(15):1372-1375. 被引量：20
  • 3Ray K K, Nazer B, Cairns R, et al. Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes [J]. J Thromb Thrombolysis, 2010,30( 1 ) : 10-13.
  • 4Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction [J]. J Am Coll Cardiol, 2009,54(23): 2157-2163.
  • 5Di Sciascio G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial [J]. J Am Coll Cardiol, 2009,54(6):558-565.
  • 6Li X, Cui Q, Kao C, et al. Lovastatin inhibits adipogenie and stimulates osteogenic differentiation by suppressing PPARgamma2 and increasing Cbfal/Runx2 expression in bone marrow mesenchymal cell cultures [J]. Bone, 2003,33 (4): 652-659.
  • 7Morrow D A, Rifai N, Antman E M, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coro-nary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction [J]. J Am Coil Cardiol, 1998,31 (7) : 1460-1465.
  • 8Wang T J, Gona P, Larson M G, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death [J]. N Engl J Med, 2006,355(25):2631-2639.
  • 9Cho YK,Hur SH,Han CD,et al.Comparison of Ezetimibe/Simvastatin 10/20mg Versus Atorvastatin 20mg in Achieving a Target Low Density Lipoprotein-Cholesterol Goal for Patients with Very High Risk[J].Korean Circ J,2011,41(3):149-153.
  • 10潘长玉.中华医学继续教育视听杂志/综合分册[M].北京:中华医学电子音像出版社,2002:3-15.

引证文献6

二级引证文献46

现代医院
2009年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部